Modality
ADC
MOA
KRASG12Ci
Target
EGFR
Pathway
Notch
Gastric CaNSCLC
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
→ Sep 2029
Phase 1Current
NCT03499368
2,291 pts·NSCLC
2021-04→2029-09·Active
NCT03408745
2,077 pts·NSCLC
2017-11→2025-04·Recruiting
4,368 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-04-0512mo agoPh2 Data· NSCLC
2026-01-202mo agoConference· Gastric Ca
2029-09-283.5y awayPh2 Data· NSCLC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2025-04-05 · 12mo ago
NSCLC
Conference
2026-01-20 · 2mo ago
Gastric Ca
Ph2 Data
2029-09-28 · 3.5y away
NSCLC
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03499368 | Phase 1/2 | NSCLC | Active | 2291 | Biomarker |
| NCT03408745 | Phase 1/2 | NSCLC | Recruiting | 2077 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |